Saxo Spotlight: What’s on the radar for investors & traders this week? Banking woes vs. inflation concerns, China PMIs and earnings on tap

Saxo Spotlight: What’s on the radar for investors & traders this week? Banking woes vs. inflation concerns, China PMIs and earnings on tap

APAC Strategy Team

Summary:  Market is likely to continue to focus on banking sector woes with First Republic and Deutsche Bank in focus at the start of the week. But eco data out from US (Feb PCE) and Eurozone (flash March CPI) may bring some focus back on inflation, and we also get a host of central bank speakers on the wires. China reopening story will also be on test again as PMIs for March are reported along with some key earnings from EV giant BYD, oil companies like PetroChina and CNOOC, top lithium producer Gangfeng and property developer Country Garden.

The shockwave from the writing down of the Credit Suisse’s AT1 bonds lingers

In spite of statements issued by the European Central Bank and the Bank of England in attempts to calm investor jitters stemming from the complete writing down of Credit Suisse’s Additional Tier-1 (AT1) debts, prices of AT1 bonds and other subordinated debts issued by European banks plunged. As Saxo’s Head of Equity Strategy, Peter Garnry, highlighted in his article, the cost of capital for European banks has soared. After 2008 Great Financial Crisis, European banks have been relying on AT1 as an important source of capital. Across the largest European banks, it is estimated that AT1 debts account for over 10% of Tier-1 capital and around 2% of risk-weighted assets. Banks will be damned if not calling the AT1 debts on call dates by both higher reset coupons as well as reputation risks and will also be damned by the anticipated high costs of refinancing by issuing new AT1 debts or common shares. Investors will monitor closely how banks handle bonds on calls and coupon resets and how investors react to it.

Is inflation still a problem in the US?

While the focus has quickly turned to banking sector concerns, the 25bps Fed rate hike and 50bps ECB hike this month is proof that central bankers are still more worried about inflation. Fed’s preferred inflation gauge, the PCE, will be out for February this week on Friday. February core CPI came in higher than expected on a MoM basis while the PPI was cooler. So expectations on PCE are rather mixed. Core PCE is expected to rise 0.4% MoM in February, cooling vs. the +0.6% in January, while the annual rate of core PCE is seen firm at 4.7% YoY, as per the Bloomberg consensus. Market continues to price in about 100bps of rate cuts for this year, defying the Fed’s latest dot plot projections, and another miss in PCE could further give weight to the market expectations. On the other hand, the PCE print will likely have to be extremely hot to shift focus away from banking troubles.

Market implication: A weaker-than-expected print could bring bond yields lower, boosting rate-sensitive tech stocks. USD could fall, mostly against the yield-sensitive Japanese yen as well as precious metals like Gold and Silver.

ECB may not waver even with a big slide in Eurozone inflation

Euro-area headline inflation is expected to see a significant slide in March, with Bloomberg consensus expecting the flash headline CPI to soften to 7.1% YoY from 8.5% in February. This is mainly due to the large base effects in energy as we hit the one-year mark for the invasion of Ukraine which led to a sudden spurt in European prices. But the base effect factor may mean that this easing of Europe’s inflation falls short to ease market’s tightening expectations for the ECB. Core inflation is still expected to remain hot, and come in at 5.7% YoY vs. 5.6% previously.

Market implication: A stronger-than-expected core CPI for the Eurozone could fuel further gains in EURUSD, as long as further bank stress remains contained in Europe.

Nasdaq 100 seen as a shelter play, up 17% this quarter, amid the worst banking sector turmoil since the GFC. Watch for end of quarter rebalancing

It’s important to reflect on market moves to see where momentum is and what could be subject to end of quarter rebalancing. With bond yields continuing to fall to new lows, down for the 3rd week, and the US dollar index down for the second, the Nasdaq 100 has continued to hit new highs, moving up 17% this quarter while the KBW Bank Index has shed 22% this quarter. Quality Mega-cap tech stocks with strong cash flows are being favoured amid the uncertainty with companies with robust balance sheets in focus. Nvidia share are up the most this quarter, up 83% as its datacentre and networking business are being seen as a defensive play. Meanwhile Meta shares up are 71% with investors buying into the fact that Meta’s revenue is expected to rise in 2023 and recover from the prior drop. Tesla shares are also doing this quarter, up 54% as Tesla has cut costs, while the lithium price is down 47% in six months which is helping Tesla’s bottom line.

China’s PMIs set to moderate while stay in expansion

According to the survey by Bloomberg, the March PMI data scheduled to release this week in China are to moderate from the strong levels in February. In March, the official NBS Manufacturing PMI is expected to come at 51.7 (February: 52.6) and Non-manufacturing PMI to drop to 54.9 (February: 56.3). The Caixin China PMI Manufacturing is expected to edge down to 51.2 from 51.6.

The March Emerging Industries PMI released earlier decelerated to 56.1 from the elevated 62.5 in February. Steel demand data coming out recently also suggested potentially some deceleration in manufacturing and construction activities in March. Seasonality may have made an impact as well as expert orders tended to be front-loaded and only to pick up gradually again after the Chinese New Year.

Market implication: Investors are impatiently waiting for growth acceleration in the Chinese economy to validate the notion of reopening trade. Turning into the wrong direction in data about the real economy may stir disappointment into investors’ deliberations.

Monthly Australia CPI; the next catalyst for the Australian dollar, local gold price and real estate linked stocks

The February CPI report is expected to show inflation fell in the month, from 7.4% YoY to 7.2%, which would support the case for the Reserve Bank of Australia to pause rate hikes at its April board meeting. This could spell further downward pressure on the Australian dollar which has been range bound for weeks. That said, if we do see a drop in inflation, Australian bond yields will likely continue to fall and that would underpin higher prices in Australian dollar gold. This scenario supports further upside in Australian gold miners shares, with Newcrest Mining shares already up 27% this year. The drop in Australian bond yields from a smaller CPI print, also support property facing companies shares continuing to rebound; with Domain, and REA already over 20% this quarter.  

The competition landscape in the China EV industry in focus

After the expiration of EV purchase subsidies at the end of last year, an intensifying price war among EV manufacturers has been front and center in the mind of investors when looking at EV stocks. The Q4 results and outlook guidance from the EV industry leader BYD (01211:xhkg) this Tuesday will be closely analysed by investors to gauge the trend in the industry. BYD is reportedly going to cut prices in new models by RMB 60-80K and older models by more than RMB150K.

Chip maker Micron and drug story giant, Walgreens results outlooks are on watch, as a proxy for what to expect from both industries this year

Chip maker, Micron Technology shares have been outperforming the Nasdaq 100, and are up 21% this year, ahead of the company reporting quarterly results after market Tuesday. Its outlook will be watched closely following the memory chipmaker’s cost-cutting efforts, from headcount reductions to executive compensation cuts, which take hold this quarter. That said, consensus expects further YoY declines in both EPS and revenue. Meanwhile, drug store giant, Walgreens Boots reports before the bell Tuesday and could see restructure and capital plans scrutinized, while investors could also react to the drugstore halting the sale of abortion-pills in several US states. Walgreens shares are down 14% this year.

Macro data on watch this week:

Monday 27 March

  • Germany IFO Business Survey (Mar)
  • Germany Retail Sales (Feb)
  • UK BOE Bailey speaks
  • US Dallas Fed Manufacturing Activity Index (Mar)
  • China Industrial Profits (Feb)

Tuesday, 28 March

  • Australia Retail Sales (Feb)
  • UK Bailey Testifies on SVB
  • US Senate Banking Committee to hold first hearing on SVB collapse
  • US Advance Goods Trade Balance (Feb)
  • US Consumer Confidence (Mar)

Wednesday, 29 March

  • Australia CPI (Feb)
  • Bank of Thailand rate decision
  • German GfK Consumer Confidence (Apr)
  • UK BOE Mann speaks
  • US House FSA hearing on SVB

Thursday, 30 March

  • Germany CPI (Mar P)
  • US Initial Jobless Claims (25-Mar)
  • US GDP (Q4 T)
  • US Treasury Secretary Yellen and Fed’s Barkin speak

Friday, 31 March

  • Japan Jobless Rate (Feb)
  • Japan Tokyo CPI (Mar)
  • China PMIs (Mar)
  • UK GDP (Q4 F)
  • France CPI (Mar P)
  • Italy CPI (Mar P)
  • Eurozone CPI (Mar P)
  • US PCE (Feb)
  • US Univ. of Michigan Sentiment (Mar F)


Earnings on watch this week:

  • Monday: BioNTech, Carnival
  • Tuesday: BYD, Nongfu Spring, Micron Technology, Lululemon Athletica, Walgreens Boots Alliance
  • Wednesday: Constellation Software, Cintas, Paychex
  • Thursday: Kweichow Moutai, Great Wall Motor, H&M

Saxo Capital Markets (Australia) Limited prepares and distributes information/research produced within the Saxo Bank Group for informational purposes only. In addition to the disclaimer below, if any general advice is provided, such advice does not take into account your individual objectives, financial situation or needs. You should consider the appropriateness of trading any financial instrument as trading can result in losses that exceed your initial investment. Please refer to our Analysis Disclaimer, and our Financial Services Guide and Product Disclosure Statement. All legal documentation and disclaimers can be found at

The Saxo Bank Group entities each provide execution-only service. Access and use of Saxo News & Research and any Saxo Bank Group website are subject to (i) the Terms of Use; (ii) the full Disclaimer; and (iii) the Risk Warning in addition (where relevant) to the terms governing the use of the website of a member of the Saxo Bank Group.

Saxo News & Research is provided for informational purposes, does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. No representation or warranty is given as to the accuracy or completeness of this information. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. No Saxo Bank Group entity shall be liable for any losses that you may sustain as a result of any investment decision made in reliance on information on Saxo News & Research.

To the extent that any content is construed as investment research, such content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication.

None of the information contained here constitutes an offer to purchase or sell a financial instrument, or to make any investments.Saxo Capital Markets does not take into account your personal investment objectives or financial situation and makes no representation and assumes no liability as to the accuracy or completeness of the information nor for any loss arising from any investment made in reliance of this presentation. Any opinions made are subject to change and may be personal to the author. These may not necessarily reflect the opinion of Saxo Capital Markets or its affiliates.

Please read our disclaimers:
- Full Disclaimer (
- Analysis Disclaimer (
- Notification on Non-Independent Investment Research (

Saxo Capital Markets (Australia) Limited
Suite 1, Level 14, 9 Castlereagh St
Sydney NSW 2000

Contact Saxo

Select region


The Saxo trading platform has received numerous awards and recognition. For details of these awards and information on awards visit

Saxo Capital Markets (Australia) Limited ABN 32 110 128 286 AFSL 280372 (‘Saxo’ or ‘Saxo Capital Markets’) is a wholly owned subsidiary of Saxo Bank A/S, headquartered in Denmark. Please refer to our General Business Terms, Financial Services Guide, Product Disclosure Statement and Target Market Determination to consider whether acquiring or continuing to hold financial products is suitable for you, prior to opening an account and investing in a financial product.

Trading in financial instruments carries various risks, and is not suitable for all investors. Please seek expert advice, and always ensure that you fully understand these risks before trading. Saxo Capital Markets does not provide ‘personal’ financial product advice, any information available on this website is ‘general’ in nature and for informational purposes only. Saxo Capital Markets does not take into account an individual’s needs, objectives or financial situation. The Target Market Determination should assist you in determining whether any of the products or services we offer are likely to be consistent with your objectives, financial situation and needs.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the US and other countries. AppStore is a service mark of Apple Inc.

The information or the products and services referred to on this website may be accessed worldwide, however is only intended for distribution to and use by recipients located in countries where such use does not constitute a violation of applicable legislation or regulations. Products and Services offered on this website is not intended for residents of the United States and Japan.

Please click here to view our full disclaimer.